Moderna Stops mRNA COVID Biologics Plant Construction in Kenya
Moderna, Inc. announced recently that it has suspended its efforts to build a $200–$500 million mRNA (messenger ribonucleic acid) biologics manufacturing facility in Kenya while it determines projected future demand for mRNA biologics in Africa. Company officials concluded that, since the end of the COVID pandemic, interest in COVID-19 biologics in Kenya and Africa has […]
